0000914475-24-000100.txt : 20240403
0000914475-24-000100.hdr.sgml : 20240403
20240403164407
ACCESSION NUMBER: 0000914475-24-000100
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240401
FILED AS OF DATE: 20240403
DATE AS OF CHANGE: 20240403
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Delaet Ingrid
CENTRAL INDEX KEY: 0001965808
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22705
FILM NUMBER: 24819580
MAIL ADDRESS:
STREET 1: C/O NEUROCRINE BIOSCIENCES, INC.
STREET 2: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC
CENTRAL INDEX KEY: 0000914475
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 330525145
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 617-7600
MAIL ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
wk-form4_1712177026.xml
FORM 4
X0508
4
2024-04-01
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001965808
Delaet Ingrid
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
0
1
0
0
Chief Regulatory Officer
1
Common Stock
2024-04-01
4
M
0
272
79.02
A
7779
D
Common Stock
2024-04-01
4
S
0
272
137.30
D
7507
D
Non-Qualified Stock Option
79.02
2024-04-01
4
M
0
272
79.02
D
2032-01-31
Common Stock
272
5172
D
The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
The option was granted January 31, 2022 and vests in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032.
/s/ Darin Lippoldt, Attorney-in-Fact
2024-04-03